Bypassing GPs to widen access to prescription-only medications through patient group directions (PGDs) is not always the safest option for patients, says NICE.
In new draft guidance on PGD schemes, NICE says authorising bodies must carefully weigh up whether or not a proposed PGD is appropriate – even if it would be legal to introduce it.
The guidance also warns that some PGDs allowing access to prescription-only medicines may not been developed following the proper procedures, with some appearing to omit the requirement to gain agreement of an ‘authorising body’.
The advice comes after the National Pharmacy Association was forced to rethink its plans to make a host of prescription-only medicines (POMs) – such as antibiotics and salbutamol inhalers – available directly from pharmacists under a PGD after opposition from the Department of Health and the GPC.
PGDs were introduced in 2000, with the aim of increasing patients’ access to POMs and promote self-care. They enable healthcare professionals to provide medicines directly to groups of patients fitting the criteria laid out in the PGD, without the need for a prescription or an instruction from a prescriber.
But NICE says that they are often introduced when independent prescribing by other healthcare professionals would be a better choice.
The new guidance states: ‘Even in some circumstances when it may be legally possible, the GDG [Guidelines Development Group] agreed that a PGD may not be the preferred and safest approach to individual situations of providing patients with the medicines they need.’
NICE calls for particular caution in decisions on PGDs covering antibacterials, stating their inclusion must not jeopardise strategies to combat increasing microbial resistance. And it stresses that, while correct dosing can be advised under a PGD, it is inappropriate for medicines requiring frequent individual dosing adjustments.
NICE also pointed out that in some cases PGDs were not being developed with the requisite agreement from authorising bodies.
It states: ‘Some organisations had processes in place to obtain the agreement of the authorising body for the PGD before proceeding to develop the PGD. In other organisations this step appeared to be omitted from the process.’
Where PGDs are not appropriate
Management of long-term conditions
Antimicrobial use – ensure clinically essential, will not jeopardise antimicrobial resistance strategies
Where frequent dosage adjustments (e.g. warfarin) or frequent/complex monitoring (e.g. immunosuppressants) needed
High-risk medicines, eg, insulin
Discover the latest in COPD at Pulse Live – our new two-day annual conference for general practice – when Dr Hilary Pinnock, a GP in Whitstable and member of the International Primary Care Respiratory Group, delivers her session on ‘What’s new in COPD?’. She provides advice on pulmonary rehabilitation and telehealth in COPD.
Pulse Live offers practical advice on key clinical and practice business topics, as well as an opportunity to debate the future of the profession, and a top range of speakers includes NICE chair designate Professor David Haslam, GPC deputy chair Dr Richard Vautrey and the Rt Hon Stephen Dorrell MP, chair of the House of Commons health committee.